Blood parameters, symptoms at presentation and adverse in-hospital outcomes of COVID-19 pneumonia in patients with hypertension
Abstract
Background: We aimed to explore the association of clinical symptoms of COVID-19 pneumonia, blood parameters on admission, and anti-hypertensive drugs with in-hospital outcomes, including length of hospital and intensive care unit (ICU) stay, receiving mechanical ventilation, degree of lung injury, and in-hospital death among patients with hypertension.
Material and methods: This retrospective study conducted in patients with newly diagnosed COVID-19 pneumonia from August 20, 2020 to September 25, 2020.
Results: A total of 182 patients with COVID-19 pneumonia were included in the present study. The patients were categorized into those with hypertension (n = 82) or without hypertension (n = 100). Patients on angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) showed no significant increase in the risk for all in-hospital outcomes. Old age [0.6 (0.5–2) p < 0.00], fever [0.3 (0.2–1.8), p < 0.00] and low lymphocytes percentage [0.3 (0.2–1.2), p < 0.00] were associated with increased risk for extensive lung injury. Old age [0.4 (0.1 = 0.7) p < 0.01], high neutrophil count [0.3 (0.2–2), p = 0.02] and low lymphocyte percentage [0.3 (0.1–0.7), p = 0.01] were associated with prolonged hospital stay while low lymphocytes percentage [0.7 (0.6–0.9), p < 0.00], old age [1.2 (1–1.4), p = 0.01] and fatigue [2 (1–4), p = 0.04] showed significant association with prolonged length of ICU stay. Low lymphocytes percentage [0.7 (0.6–1), p < 0.00], old age [1.1 (1–1.2), p = 0.01] and fatigue [2 (1.7–4), p = 0.02] were associated with increased risk for receiving mechanical ventilation. Risk for in-hospital death was associated with increased neutrophil percentage [1.2 (1–1.5), p = 0.01] and old age [1.1 (1–1.2), p = 0.03].
Conclusions: ARBs and ACEIs showed no significant association with adverse in-hospital outcomes. Old age, low lymphocytes percentage and high neutrophils percentage on admission were independent predictors for increased risk of in-hospital mortality and morbidity among COVID-19 pneumonia patients with hypertension.
Keywords: COVID-19blood parametershypertensionin-hospital outcome
References
- Renu K, Prasanna PL, Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review. Life Sci. 2020; 255: 117839.
- Babadaei MM, Hasan A, Bloukh SH, et al. The expression level of angiotensin-converting enzyme 2 determines the severity of COVID-19: lung and heart tissue as targets. J Biomol Struct Dyn. 2020 [Epub ahead of print]: 1–7.
- Landi F, Barillaro C, Bellieni A, et al. The New Challenge of Geriatrics: Saving Frail Older People from the SARS-COV-2 Pandemic Infection. J Nutr Health Aging. 2020; 24(5): 466–470.
- Wu F, Zhao Su, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798): 265–269.
- Morra ME, Van Thanh Le, Kamel MG, et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis. Rev Med Virol. 2018; 28(3): e1977.
- Matsuyama R, Nishiura H, Kutsuna S, et al. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. BMC Public Health. 2016; 16(1): 1203.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506.
- Zhao M, Wang M, Zhang J, et al. Advances in the relationship between coronavirus infection and cardiovascular diseases. Biomed Pharmacother. 2020; 127: 110230.
- Huang S, Wang J, Liu F, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res. 2020; 43(8): 824–831.
- Park JE, Jung S, Kim A, et al. MERS transmission and risk factors: a systematic review. BMC Public Health. 2018; 18(1): 574.
- Matsuyama R, Nishiura H, Kutsuna S, et al. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. BMC Public Health. 2016; 16(1): 1203.
- Jin Y, Yang H, Ji W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020; 12(4).
- Zhao K, Li R, Wu X, et al. Clinical features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis. Eur J Clin Microbiol Infect Dis. 2020; 39(12): 2279–2287.
- Gebhard C, Regitz-Zagrosek V, Neuhauser HK, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020; 11(1): 29.
- Bosso M, Thanaraj TA, Abu-Farha M, et al. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Mol Ther Methods Clin Dev. 2020; 18: 321–327.
- Vlachakis PK, Tentolouris A, Tousoulis D, et al. Current data on the cardiovascular effects of COVID-19. Hellenic J Cardiol. 2020; 61(1): 46–48.
- Shibata S, Arima H, Asayama K, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res. 2020; 43(10): 1028–1046.
- Zhou Y, Yang Q, Chi J, et al. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. 2021; 37(2): e3377–56.
- Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7): 811–818.
- Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020; 126(12): 1671–1681.
- Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020; 95(7): 834–847.
- Zhu Z, Cai T, Fan L, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis. 2020; 95: 332–339.
- Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71(15): 762–768.
- Wang D, Hu Bo, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061–1069.
- Yan X, Li F, Wang X, et al. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study. J Med Virol. 2020; 92(11): 2573–2581.